|Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents - Monitor Patents|
USPTO Class 530 | Browse by Industry: Previous - Next | All
Recent | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereofBelow are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 02/27/2014 > 10 patent applications in 9 patent subcategories.
20140058061 - Process for preparing platinum-carbene complexes: Described is a process for preparing platinum-carbene complexes.... Agent: Centre National De La Recherche Scientifique
20140058064 - Multi-drug ligand conjugates: Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of cytotoxic drugs and vitamin receptor binding ligands. The plurality of drugs may be the same or different. Similarly, the vitamin receptor binding ligands may... Agent: Endocyte, Inc.
20140058063 - Vitamin receptor binding drug delivery conjugates: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes... Agent: Endocyte, Inc.
20140058065 - Far-red fluorescent proteins with improved detectability by red excitation light: Aspects of the present disclosure are directed towards far-red monomeric fluorescent proteins that have a high level of brightness such that the proteins are visible over the autofluorescence aspects of tissue. In certain embodiments, the fluorescent proteins are derived from Entacmeae quadricolor. The fluorescent proteins are implantable in the cell... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20140058066 - Artificial polypeptide fiber and method for producing the same: An artificial polypeptide fiber of the present invention is an artificial fiber containing a polypeptide as a main component, and has a stress of 350 MPa or more and a toughness of 138 MJ/m3 or more. A method for producing an artificial polypeptide fiber of the present invention is a... Agent: Spiber Inc.
20140058067 - Immunoconjugates with an intracellularly-cleavable linkage: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.... Agent: Immunomedics, Inc.
20140058068 - Novel gh-rh analogs with potent agonistic effects: There are provided a novel series of peptide analogs of hGH-RH(1-29)NH2 and hGH-RH(1-30)NH2 which show high activities in stimulating the release of pituitary GH in animals. They retain their physiological activity in solution for extended periods of time and resist enzymic degradation in the body. These novel and useful properties... Agent:
20140058069 - Particles and other substrates useful in protein purification and other applications: The present invention generally relates to particles, including microgel particles, for purifying proteins and other species. In one aspect, the particles comprise a metal-chelating moiety, which may be distributed substantially evenly throughout the particle in certain embodiments. In some cases, the particles may be porous, and in some embodiments, the... Agent: Children's Medical Center Corporation
20140058070 - C-terminal amidation of polypeptides: There are provided compounds and methods for amidating the C-terminus of a polypeptide. The method include reacting a polypeptide which includes a C-terminal thioester or C-terminal selenoester with any one of a defined set of auxiliary molecules under conditions suitable to produce a polypeptide adduct which includes the auxiliary molecule... Agent: Astrazeneca Pharmaceuticala Lp02/20/2014 > 15 patent applications in 9 patent subcategories.
20140051828 - Methods for preparing internally constrained peptides and peptidomimetics: The present invention relates to a method for preparing a peptide having a stable, internally constrained alpha-helical, beta-sheet/beta-turn, 310-helical, or pi-helical region and a method of stabilizing an alpha-helical, beta-sheet/beta-turn, 310-helical, or pi-helical region within a peptide structure. The resulting peptides and methods of using them are also disclosed.... Agent:
20140051829 - Axmi-205 pesticidal gene and method for its use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise... Agent: Athenix Corp.
20140051830 - In-process control for the manufacture of glatiramer acetate: The present disclosure provides methods for manufacturing or producing glatiramer acetate having a Mp of 5000-9000 Da. These methods include: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid (TFA)-protected L-lysine, and L-tyrosine to generate a sample comprising intermediate-1; treating the sample comprising intermediate-1 to partially depolymerize the protected... Agent: Momenta Pharmaceuticals, Inc.
20140051831 - Method for isolating osteopontin using feeds containing cmp or casein species: The present invention pertains to a method for isolating osteopontin from a milk-derived feed containing caseino macropeptide and/or free beta casein, such as e.g. a feed based on milk serum or sweet whey. Particularly, the present method involves the use of a narrow window of pH and specific conductance of... Agent: Arla Foods Amba
20140051832 - Method for the production of recombinant human factor viii: The object of the present invention is to provide methods for the production of recombinant human Factor VIII, employing specific endoproteases, thus assuring full proteolytic processing of said factor even during its biosynthesis, consequently avoiding additional purification steps. Other objects of the present invention are the recombinant human Factor VIII... Agent: Universidade De SÃ O Paulo - Usp
20140051834 - Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function: Herein is reported an Fc-region fusion polypeptide or Fc-region conjugate comprising one to four incretin receptor ligand polypeptides and a variant human Fc-region with a mutation of the amino acid residue at position 329 and at least one further mutation of at least one amino acid selected from the group... Agent: Indiana University Research And Technology Corporation
20140051836 - Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use: Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful... Agent:
20140051835 - Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells: The present invention provides a process and methods for producing asymmetric antibodies in a mammalian expression system. The asymmetric antibodies are transiently or stably expressed and in cells that stably express the asymmetric antibody, following a rapid 2-step process of stable pool to clone, a highly pure asymmetric antibody expressing... Agent:
20140051833 - Readily isolated bispecific antibodies with native immunoglobulin format: The invention relates to antigen-binding proteins or antibodies having heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least one or two amino acid(s) that allows for isolation of the antigen-binding protein based on a differential affinity of an immunoglobulin heavy chain and a modified/mutated immunoglobulin... Agent:
20140051837 - Axmi-205 pesticidal gene and method for its use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise... Agent: Athenix Corp.
20140051838 - Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Agensys, Inc.
20140051840 - Arsenic complexes for potential diagnostic applications: The present invention provides radioactive arsenic complex useful in diagnostic and therapeutic applications and methods for forming those arsenic complexes.... Agent:
20140051842 - Polynucleotide and polypeptide sequence and methods thereof: The present disclosure relates to a field of recombinant DNA therapeutics. It involves the bio-informatics design, synthesis of artificial gene for human insulin precursor including leader peptide coding sequence, cloning in an expression vector and expression in an organism, preferably Pichia pastoris. The present disclosure also relates to methods of... Agent: Bigtec Private Limited
20140051841 - Process for purifying recombinant plasmodium falciparum circumsporozoite protein: The present invention relates to processes for purifying high-quality recombinant Plasmodium falciparum circumsporozoite protein at high yields.... Agent: Pfenex Inc.02/13/2014 > 22 patent applications in 15 patent subcategories.
20140046020 - Pre-operative use of metabolic activation therapy: Metabolic Activation Therapy (MAT®) is a procedure which uses intravenous insulin pulses administered with oral glucose to deliver an insulin treatment regimen that improves the biochemistry and physiology of diabetic and non-diabetic individuals. If implemented preoperatively to patients with a history of hyperglycemia who undergo surgical and other stress inducing... Agent:
20140046021 - Self-magnetic metal-salen complex compound: The molecular structures of metal-salen complexes which exerts pharmacological effects are clarified and the metal-salen complexes having such molecular structures and their derivatives are provided. A metal-salen complex compound is characterized in that a metal atom part in each of multiple molecules of the metal-salen complex or its derivative is... Agent: Ihi Corporation
20140046022 - Fluorene compound: Particular compounds having a fluorene skeleton are superior in broad utility and stability, as a protecting reagent for liquid phase synthesis of amino acids and/or peptides.... Agent: Ajinomoto Co., Inc.
20140046023 - Specific sorbent for binding proteins and peptides, and separation method using the same: Sorbent comprising a solid support material, the surface of which comprises first residues comprising a binuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms N, O, S, and second residues comprising a mononuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms N,... Agent: Instraction Gmbh
20140046025 - Device and method for production and analysis of prions: The invention provides a method for producing prion protein having an aggregated conformation by contacting native conformation prion protein with aggregated conformation prion protein in a liquid preparation and subjecting this to at least one cycle or to a number of cycles of application of shear-force for fragmenting aggregates of... Agent:
20140046024 - Evaluation of copolymer diethylamide: Methods of analyzing glatiramer acetate (GA) or a polymeric precursor thereof are provided. The methods can include determining a level of one or more diethylamide-modified amino acids in a sample comprising GA or a polymeric precursor thereof, and selecting at least a portion of the sample based on the assessment... Agent: Momenta Pharmaceuticals, Inc.
20140046026 - Superagonists and antagonists of interleukin-2: Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules... Agent: Board Of Trustees Of The Leland Stanford Junior University
20140046027 - Double click technology: The present invention concerns a method of modifying the surface of a cellulosic material, wherein a modifying compound is attached to the cellulosic material through a linker, which linker is a conjugate that has been activated by functionalization prior to adsorption to form an activated conjugate, and wherein the entire... Agent: Aalto University Foundation
20140046028 - Method for preparing a concentrate of factor xi: The invention concerns a concentrate of human Factor XI having high specific activity prepared using a method comprising a filtration-adsorption step and a chromatography step on cation exchange resin. The concentrate obtained is fully adapted for therapeutic use as substitution therapy in cases of Factor XI deficiency.... Agent: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
20140046029 - Solid support with a grafted chain: Articles that contain a solid support with a grafted chain extending from the solid support, methods of making these articles, and various uses of the articles are described. More specifically, the grafted chain has a functional group that can react with or interact with target compound. Alternatively, the functional group... Agent: 3m Innovative Properties Company
20140046031 - Anti-il-23 antibodies, compositions, methods and uses: An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.... Agent: Janssen Biotech, Inc.
20140046030 - Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use: Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.... Agent: Sutro Biopharma, Inc.
20140046033 - Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use: The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The antibodies... Agent:
20140046034 - Antibody having activity of inhibiting hepatitus c virus (hcv) infection and use thereof: An object of the present invention is to provide an antibody inhibiting infection with hepatitis C virus (HCV). The present invention provides an anti-hepatitis C virus antibody that recognizes a whole or a part of the conformation of a hepatitis C virus particle as an epitope and binds thereto, so... Agent: Toray Industries, Inc.
20140046032 - Method of production of sialylated antibodies: The present invention relates to a method for producing an IgG antibody, wherein at least 80% of the said antibody comprises a complex, bi-antennary oligosaccharide, which contains two sialic acid residues, attached to the Fc domain of the antibody. The said method comprises the steps of introducing a mutation in... Agent: Sanofi
20140046035 - Improved production of anti-peptide antibodies: Anti-peptide antibodies (APAs) are extremely important tools for biomedical research. Many important techniques, such as immunoblots, ELISA immunoassays, immunocytochemistry, and protein microarrays are intrinsically linked to APA function and completely dependent on APA quality. Unfortunately, not all commercially-available APAs have good antigen binding characteristics; as a result, researchers are often... Agent: Bioo Scientific Corporation
20140046036 - Method for cancer immunotherapy: wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4... Agent: Chugai Seiyaku Kabushiki Kaisha
20140046037 - Novel immunoglobulin-binding proteins with improved specificity: The present invention relates to modified immunoglobulin-binding proteins, e.g., Staphylococcus protein A, having improved binding specificity for immunoglobulins and methods of making and using the same.... Agent: Emd Millipore Corporation
20140046038 - Method of purifying protein: The present invention relates to a method for purifying a protein by separating the protein from impurities in a non-adsorption mode using an activated carbon. In particular, the present invention relates to a method for purifying an antibody using the activated carbon instead of protein A affinity chromatography.... Agent: Kyowa Hakko Kirin Co., Ltd
20140046039 - Antibodies directed against influenza: Antibodies or antibody fragments, wherein the antibody or the fragment binds HA domain of influenza virus (e.g. H1N1, H5N1, or both). Also described are cloned human antibodies that bind influenza... Agent: Emory University
20140046040 - Method for selective derivatization of oligohistidine sequence of recombinant proteins: Methods and compositions for the selective derivatization of a oligohistidine-tagged recombinant protein. A modifying compound comprised of an imidazole reactive group, a linker, and a ligating group is contacted with the recombinant protein, and a cooperative bond forms between the ligating group and the oligohistidine tag in the presence of... Agent: Clarkson University
20140046041 - Compositions comprising lignocellulosic biomass and organic solvent: The present disclosure relates, at least in part, to compositions comprising lignocellulosic biomass and an organic solvent wherein the lignocellulosic biomass comprises 35% or greater of lignin material. The present disclosure relates, at least in part, to compositions comprising lignocellulosic biomass and an organic solvent wherein the lignocellulosic biomass comprises... Agent: Lignol Innovations Ltd.02/06/2014 > 16 patent applications in 14 patent subcategories.
20140039153 - Cancer imaging and treatment: wherein: P1 and P2, which may be the same or different, are cyclic oligopeptide moieties, at least one of P1 and P2 having the motif B-Arg or B-(Me)Arg within the cyclic moiety, wherein B is a basic amino acid, a derivative thereof, or phenylalanine or a derivative thereof; S1 and... Agent: Technische Universitat Munchen
20140039154 - Protein disulfide isomerase assay method for the in vitro diagnosis of colorectal cancer: A method for the in vitro diagnosis of colorectal cancer that comprises determining the presence of the protein disulfide isomerase tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-PDI monoclonal antibody directed against a PDI epitope chosen from the... Agent: Biomerieux
20140039155 - Amyloid-beta peptide crystal structure: The invention relates provides a novel crystal structure of the fibrillogenic part of amyloid β-peptide (Aβ). More specifically the crystal structure is Aβ-IgNAR and, accordingly the present invention also relates to selecting and/or designing compounds that modulate amyloid β-peptide (Aβ) activity using techniques such as in silico screening and crystal... Agent: Commonwealth Scientific And Industrial Research Organisation
20140039156 - High-throughput screening for compounds modulating expression of cellular macro-molecules: A method of screening for compounds that module expression of specific macromolecules, the “target”. The method is particularly useful in that it does not require separation of target-bound and excess ligand and therefore enables, but is not limited to, High Throughput Screening for compounds that increase or decrease the levels... Agent: The Scripps Research Institute
20140039157 - Methods and composition for measuring the amount of vitamin d derivatives: Methods and compositions for measuring the amount of vitamin D derivatives are disclosed. Fluorescence Resonance Energy Transfer (FRET) in combination with a modified ligand-binding domain of the vitamin D receptor (LBD-VDR) to measure vitamin D derivatives are also disclosed.... Agent: OpkoIPHoldings, Inc.
20140039158 - Polymeric conjugates and methods of preparing the same: Methods of preparing polymer target conjugates which are substantially free of polymer attachment on the N-terminal of the targets are provided. Also provided are compositions comprising a plurality of polymer-polypeptide conjugates, said polymer-polypeptide conjugate comprising a polypeptide covalently attached to at least one polymer through an epsilon amino group of... Agent: Belrose Pharma, Inc.
20140039159 - Electroactive biopolymer optical and electro-optical devices and method of manufacturing the same: A method of manufacturing a biopolymer optical device includes providing a polymer, providing a substrate, casting the polymer on the substrate, and enzymatically polymerizing an organic compound to generate a conducting polymer between the provided polymer and the substrate. The polymer may be a biopolymer such as silk and may... Agent:
20140039160 - Novel process for the preparation of a virus-inactivated fv concentrate starting from human plasma, scalable to industrial level: The present invention provides a process for purifying FV starting from human plasma or a fractionation intermediate thereof, that is simple, scalable to the industrial level and relatively inexpensive compared to the methods described in the literature to date. The invention consists of the use of two anion exchange chromatography... Agent: Kedrion S.p.a.
20140039161 - Method for extracting igy (r-livetin) from egg yolk: A method for extracting IgY (γ-livetin) from yolk is disclosed, which comprises the following steps: (A) providing a buffer solution, a yolk sample, and an inorganic salt solution; (B) diluting the yolk sample with the buffer solution to obtain a mixture, stirring the mixture for a predetermined time, and performing... Agent: National Taiwan Normal University
20140039163 - Cholesterol-dependent cytolysin variant and use thereof in dds: The present invention provides a carrier capable of delivering a medical agent capsule encapsulating a medical agent to various target cells and tissues to cause the medical agent to be taken therein in an efficient and highly safe manner, and a drug delivery system using the carrier. The carrier has... Agent:
20140039162 - Displaying native human ige neutralizing fcerla-contacting ige b-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold: Vaccine displaying native antigenic loops of immunoglobulin E is critical for eliciting neutralizing anti-IgE antibodies. The embodiment of the invention enables the display of native antigenic IgE receptor-contacting loops as IgE B-cell vaccines via three steps of constraining methods. The loops of multiple antigenic B-cell epitopes can be molecularly grafted... Agent:
20140039164 - Therapeutic human anti-il-1r1 monoclonal antibody: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.... Agent: Amgen Inc.
20140039165 - Anti-nr10 antibody and use thereof: The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.... Agent: Chugai Seiyaku Kabushiki Kaisha
20140039166 - Silica nanoparticle for diagnostic imaging, method for producing the same, and biosubstance labeling agent: A silica nanoparticle for diagnostic imaging that may be capable of use for X-ray CT, fluorescent imaging, or the like, and have high emission intensity. A method for producing such a silica nanoparticle for diagnostic imaging is provided. Also, a biosubstance labeling agent using the silica nanoparticle for diagnostic imaging... Agent: Konica Minolta, Inc.
20140039167 - Polymer derivatives comprising an acetal or ketal branching point: The invention conjugates that can be prepared by contacting a polymer comprising an acetal or ketal branching point with a pharmacologically active agent under conditions suitable to form a covalent attachment between the polymer and the pharmacologically active agent.... Agent: Nectar Therapeutics
20140039168 - Lignosulfonate compounds for solid ink applications: ePrevious industry: Synthetic resins or natural rubbers -- part of the class 520 series
Next industry: Organic compounds -- part of the class -570 series
RSS FEED for 20140227:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents we recommend signing up for free keyword monitoring by email.
Results in 0.33764 seconds